Immune Control of AIDS Progression by an Adenovirus-Based Therapeutic Vaccination in Acute Simian Immunodeficiency Virus-Infected Macaques

Abstract

Therapeutic vaccinations that enhance human immunodeficiency virus (HIV)-specific immunity hold promise for reducing reliance on antiretroviral therapy (ART). We previously developed an adenovirus vector-infected peripheral blood mononuclear cell (AVIP) as a prophylactic strategy that enhanced cellular immunity in macaques and significantly reduced set-point and peak simian immunodeficiency virus (SIV) loads following SIV challenge. However, its therapeutic efficacy remains to be fully explored. In this study, we improved AVIP by enhancing adenovirus entry into peripheral blood mononuclear cells (PBMCs) through in vitro co-incubation with granulocyte-macrophage colony-stimulating factor (GM-CSF). We constructed adenoviruses carrying SIV group-specific antigen (Gag), envelope (Env), and polymerase (Pol) and evaluated the therapeutic potential of autologous AVIP infusion in acute SIV-infected macaques. Compared with ART alone, AVIP in combination with ART elicited robust cellular immunity against SIV, effectively controlled SIV replication during ART, and delayed viral rebound and acquired immunodeficiency syndrome (AIDS) progression after ART discontinuation. Notably, 80% of macaques in AVIP+ART group maintain plasma virus control for at least 100 days after ART interruption. This sustained viral control is associated with vaccine-induced Pol-specific immune responses and reduced CD38 expression on CD8⁺ T cells. These findings support further investigation of AVIP as a therapeutic strategy against acute HIV infection.

Keywords

adenovirus vector / granulocyte-macrophage colony-stimulating factor (GM-CSF) / human immunodeficiency virus (HIV) / rhesus macaque / simian immunodeficiency virus (SIV) / therapeutic vaccine

References

[1] P. M. Sharp and B. H. Hahn, “Origins of HIV and the AIDS Pandemic,” Cold Spring Harbor Perspectives in Medicine 1, no. 1 (2011): a006841.

[2] S. Li, C. Moog, T. Zhang, and B. Su, “HIV Reservoir: Antiviral Immune Responses and Immune Interventions for Curing HIV Infection,” Chinese Medical Journal 135, no. 22 (2022): 2667-2676.

[3] J. D. Gunst, J. Gohil, J. Z. Li, et al., “Time to HIV Viral Rebound and Frequency of Post-Treatment Control After Analytical Interruption of Antiretroviral Therapy: An Individual Data-Based Meta-Analysis of 24 Prospective Studies,” Nature Communications 16, no. 1 (2025): 906.

[4] H. Zhao, Y. He, X. Ling, et al., “Profiles of Lymphocyte Subtypes in HIV-Infected People With Different Immunologic Responses to Antiretroviral Therapy,” Journal of Medical Virology 96, no. 11 (2024): e70081.

[5] P. Xu, D. Yuan, C. Moog, B. Su, “Efforts Toward Achieving the Goal of Ending AIDS by 2030: From Antiretroviral Drugs to HIV Vaccine and Cure Research,” Science China Life Sciences 68, no. 6 (2025): 1849-1851.

[6] Z. Chen and B. Julg, “Therapeutic Vaccines for the Treatment of HIV,” Translational Research 223 (2020): 61-75.

[7] T. Fan, M. Zhang, J. Yang, Z. Zhu, W. Cao, C. Dong, “Therapeutic Cancer Vaccines: Advancements, Challenges, and Prospects,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 450.

[8] L. Feng, Q. Wang, C. Shan, et al., “An Adenovirus-Vectored COVID-19 Vaccine Confers Protection From SARS-CoV-2 Challenge in Rhesus Macaques,” Nature Communications 11, no. 1 (2020): 4207.

[9] P. Li, Q. Wang, Y. He, et al., “Booster Vaccination Is Required to Elicit and Maintain COVID-19 Vaccine-Induced Immunity in SIV-Infected Macaques,” Emerging Microbes and Infections 12, no. 1 (2023): e2136538.

[10] H. Li, C. Yang, L. Yin, et al., “Comparative Immunogenicity of Monovalent and Bivalent Adenovirus Vaccines Carrying Spikes of Early and Late SARS-CoV-2 Variants,” Emerging Microbes and Infections 13, no. 1 (2024): 2387447.

[11] X. Wang, C. Sun, P. Li, et al., “Vaccine Engineering With Dual-Functional Mineral Shell: A Promising Strategy to Overcome Preexisting Immunity,” Advanced Materials 28, no. 4 (2016): 694-700.

[12] M. W. Kinyanjui, D. Ramos-Barbon, A. Villeneuve, E D. Fixman, “Enhanced Transduction of Antigen-Stimulated T Lymphocytes With Recombinant Retroviruses Concentrated by Centrifugal Filtration,” Journal of Immunological Methods 314, no. 1-2 (2006): 80-89.

[13] C. Sun, L. Feng, Y. Zhang, et al., “Circumventing Antivector Immunity by Using Adenovirus-Infected Blood Cells for Repeated Application of Adenovirus-Vectored Vaccines: Proof of Concept in Rhesus Macaques,” Journal of Virology 86, no. 20 (2012): 11031-11042.

[14] T. Somfai, N. Kashiwazaki, M. Ozawa, et al., “Effect of Centrifugation Treatment Before Vitrification on the Viability of Porcine Mature Oocytes and Zygotes Produced in Vitro,” Journal of Reproduction and Development 54, no. 3 (2008): 149-155.

[15] B. Becher, S. Tugues, M. Greter, “GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation,” Immunity 45, no. 5 (2016): 963-973.

[16] H. M. Mehta, M. Malandra, S. J. Corey, “G-CSF and GM-CSF in Neutropenia,” Journal of Immunology 195, no. 4 (2015): 1341-1349.

[17] F. Feng, J. Zhao, P. Li, R. Li, L. Chen, C. Sun, “Preexisting Virus-Specific T Lymphocytes-Mediated Enhancement of Adenovirus Infections to Human Blood CD14+ Cells,” Viruses 11, no. 2 (2019): 154.

[18] Y. Kim, D. Y. Lee, J. U. Choi, et al., “Optimized Conditions for Gene Transduction Into Primary Immune Cells Using Viral Vectors,” Scientific Reports 13, no. 1 (2023): 12365.

[19] C. Wu, Y. He, J. Zhao, et al., “Exacerbated AIDS Progression by PD-1 Blockade During Therapeutic Vaccination in Chronically Simian Immunodeficiency Virus-Infected Rhesus Macaques After Interruption of Antiretroviral Therapy,” Journal of Virology 96, no. 3 (2022): e0178521.

[20] Y. He, C. Wu, Z. Liu, et al., “Arsenic Trioxide-Induced Apoptosis Contributes to Suppression of Viral Reservoir in SIV-Infected Rhesus Macaques,” Microbiology Spectrum 11, no. 5 (2023): e0052523.

[21] D. R. Collins, G. D. Gaiha, B D. Walker, “CD8⁺ T Cells in HIV Control, Cure and Prevention,” Nature Reviews Immunology 20, no. 8 (2020): 471-482.

[22] G. G. Sherman, L. E. Scott, J. S. Galpin, et al., “CD38 Expression on CD8(+) T Cells as a Prognostic Marker in Vertically HIV-Infected Pediatric Patients,” Pediatric Research 51, no. 6 (2002): 740-745.

[23] L. Lu, J. Wang, Q. Yang, X. Xie, Y. Huang, “The Role of CD38 in HIV Infection,” AIDS Research and Therapy 18, no. 1 (2021): 11.

[24] K E. Stephenson, “Therapeutic Vaccination for HIV: Hopes and Challenges,” Current Opinion in HIV and AIDS 13, no. 5 (2018): 408-415.

[25] A. Urbina, R. Godoy-Silva, M. Hoyos, M. Camacho, “Acute Hydrodynamic Damage Induced by SPLITT Fractionation and Centrifugation in Red Blood Cells,” Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 1020 (2016): 53-61.

[26] M. Delahaye, K. Lawrence, S. J. Ward, M. Hoare, “An Ultra Scale-Down Analysis of the Recovery by Dead-End Centrifugation of Human Cells for Therapy,” Biotechnology and Bioengineering 112, no. 5 (2015): 997-1011.

[27] C. T. Berger, N. Frahm, D. A. Price, et al., “High-Functional-Avidity Cytotoxic T Lymphocyte Responses to HLA-B-Restricted Gag-Derived Epitopes Associated With Relative HIV Control,” Journal of Virology 85, no. 18 (2011): 9334-9345.

[28] C. A. Bricault, K. Yusim, M. S. Seaman, et al., “HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design,” Cell Host & Microbe 25, no. 1 (2019): 59-72.

[29] R. P. Payne, H. Kloverpris, J. B. Sacha, et al., “Efficacious Early Antiviral Activity of HIV Gag- and Pol-Specific HLA-B 2705-Restricted CD8⁺ T Cells,” Journal of Virology 84, no. 20 (2010): 10543-10557.

[30] D. Persaud, H. Gay, C. Ziemniak, et al., “Absence of Detectable HIV-1 Viremia After Treatment Cessation in an Infant,” New England Journal of Medicine 369, no. 19 (2013): 1828-1835.

[31] B. J. Macatangay, C R. Rinaldo, “Preserving HIV-Specific T Cell Responses: Does Timing of Antiretroviral Therapy Help?,” Current Opinion in HIV and AIDS 10, no. 1 (2015): 55-60.

[32] J. Fan, H. Liang, T. Shen, et al., “Early Env-Specific CTLs Effectively Suppress Viral Replication in SHIV Controller Macaques,” Cellular Immunology 331 (2018): 30-37.

[33] T. Tipoe, A. Ogbe, M. Lee, et al., “Impact of Antiretroviral Therapy During Primary HIV Infection on T-Cell Immunity After Treatment Interruption,” European Journal of Immunology 54, no. 11 (2024): e2451200.

[34] N. Borthwick, T. Ahmed, B. Ondondo, et al., “Vaccine-Elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1,” Molecular Therapy 22, no. 2 (2014): 464-475.

[35] C. Sun, Z. Chen, X. Tang, et al., “Mucosal Priming With a Replicating-Vaccinia Virus-Based Vaccine Elicits Protective Immunity to Simian Immunodeficiency Virus Challenge in Rhesus Monkeys,” Journal of Virology 87, no. 10 (2013): 5669-5677.

[36] M A. Kolber, “CD38⁺CD8⁺ T-Cells Negatively Correlate With CD4 Central Memory Cells in Virally Suppressed HIV-1-Infected Individuals,” AIDS 22, no. 15 (2008): 1937-1941.

[37] V. Appay, A D. Kelleher, “Immune Activation and Immune Aging in HIV Infection,” Current Opinion in HIV and AIDS 11, no. 2 (2016): 242-249.

[38] A. Schuetz, C. Deleage, I. Sereti, et al., “Initiation of ART During Early Acute HIV Infection Preserves Mucosal Th17 Function and Reverses HIV-Related Immune Activation,” PLoS Pathogens 10, no. 12 (2014): e1004543.

[39] H. Wang, P. Li, M. Zhang, et al., “Vaccine With Bacterium-Like Particles Displaying HIV-1 gp120 Trimer Elicits Specific Mucosal Responses and Neutralizing Antibodies in Rhesus Macaques,” Microbial Biotechnology 15, no. 7 (2022): 2022-2039.

[40] C. Wu, J. Zhao, R. Li, et al., “Modulation of Antiviral Immunity and Therapeutic Efficacy by 25-Hydroxycholesterol in Chronically SIV-Infected, ART-Treated Rhesus Macaques,” Virologica Sinica 36, no. 5 (2021): 1197-1209.

[41] Q. Yang, F. Feng, P. Li, et al., “Arsenic Trioxide Impacts Viral Latency and Delays Viral Rebound After Termination of ART in Chronically SIV-Infected Macaques,” Advanced Science 6, no. 13 (2019): 1900319.

[42] P. Li, F. Feng, E. Pan, et al., “Scavenger Receptor-Mediated Ad5 Entry and acLDL Accumulation in Monocytes/Macrophages Synergistically Trigger Innate Responses Against Viral Infection,” Virology 519 (2018): 86-98.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.